CRISPR Therapeutics stock performance and Zacks Rank rating were reported on July 26, 2025, within the biomedical sector.
5 reports, 1 independent
Updated Jul 26
Gone quiet
- Reports
- 5
- Developments
- 4
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics stock performance and Zacks Rank rating were reported on July 26, 2025, within the biomedical sector.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- CRISPR Therapeutics and the broader biomedical and genetics industry were operating within the medical sector, with stock performance noted against the S&P 500 on July 16, 2025.Sub-event
CRSP stock performance and Zacks Rank rating reported on July 26, 2025.1 source
CRISPR stock performance details show it outperformed the sector over the past month but lagged the S&P 500 daily.1 source
- CRISPR Therapeutics' stock performance was reported on June 26, 2025, showing gains exceeding both the sector average and the S&P 500, evaluated using Zacks' proprietary ranking system.
Keep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksCRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know In the latest close session, CRISPR Therapeutics AG (CRSP) was down 1.97% at $64.76. This change lagged the S
- ZacksCRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade In the latest close session, CRISPR Therapeutics AG (CRSP) was down 3.05% at $66.06. The stock's performance
- Unknown outlet
- Unknown outlet
- Unknown outlet